Parallax Volatility Advisers’s Pacific Biosciences PACB Stock Holding History

Parallax Volatility Advisers’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-993	Closed	-$8.12K	–	3050
2022 Q4	$8.12K	Sell	993 -180,704	-99%	-$1.56M	﹤0.01%	2577
2022 Q3	$1.05M	Buy	+181,697	New	+$1.04M	﹤0.01%	1716
2021 Q4	–	Sell	-10,901	Closed	-$263K	–	2203
2021 Q3	$279K	Buy	+10,901	New	+$323K	﹤0.01%	1640
2021 Q2	–	Sell	-1,379	Closed	-$40.1K	–	1586
2021 Q1	$46K	Buy	+1,379	New	+$48.3K	﹤0.01%	1181
2019 Q1	–	Sell	-20,000	Closed	-$148K	–	3649
2018 Q4	$148K	Buy	+20,000	New	+$127K	﹤0.01%	1822
2018 Q2	–	Sell	-11,896	Closed	-$24K	–	2937
2018 Q1	$24K	Sell	11,896 -15,750	-57%	-$40.9K	﹤0.01%	1691
2017 Q4	$73K	Buy	+27,646	New	+$96.8K	﹤0.01%	2991

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Parallax Volatility Advisers's PACB Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 993 shares — an estimated $8.12K sold.

Parallax Volatility Advisers first reported a position in PACB in Q4 2017 and held it in 7 quarters. The position peaked at $1.05M in Q3 2022. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

Parallax Volatility Advisers reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 993 Pacific Biosciences shares in Q1 2023, an estimated $8.12K.
Parallax Volatility Advisers first reported a position in Pacific Biosciences in Q4 2017 and held it in 7 quarters.
Parallax Volatility Advisers's Pacific Biosciences position peaked at $1.05M in Q3 2022.
259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.